CN1325079C - Chinese medicine picrorhiza extract possessing anti hepatitis B virus activity and its preparation method - Google Patents
Chinese medicine picrorhiza extract possessing anti hepatitis B virus activity and its preparation method Download PDFInfo
- Publication number
- CN1325079C CN1325079C CNB2005100114874A CN200510011487A CN1325079C CN 1325079 C CN1325079 C CN 1325079C CN B2005100114874 A CNB2005100114874 A CN B2005100114874A CN 200510011487 A CN200510011487 A CN 200510011487A CN 1325079 C CN1325079 C CN 1325079C
- Authority
- CN
- China
- Prior art keywords
- solution
- northwest
- injection
- calculus bovis
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides the ethanol extract of figwortflower picrorhiza rhizome and the preparation method of the ethanol extract. The content of picroside II is not less than 70.0% and the extract has the activity of hepatitis B virus resistance, etc.
Description
Technical field
The invention provides ethanol extraction of Chinese medicine Rhizoma Picrorhizae and preparation method thereof, the content of Picroside II Amphicoside 6-Vanilloylcatalpol is no less than 70.0% in the described extract; Described extract has the anti-hepatitis virus isoreactivity.
Background technology
Hepatitis B is the disease that is caused by hepatitis B virus (HBV), is widely current in China, and crowd infection rate's height, infection rate reaches more than 35% in certain areas.According to interrelated data, hepatitis detects male patient and has reached 1.89 hundred million, and the number (carrier) nearly 400,000,000 of should not going to a doctor.Be more common in child and person between twenty and fifty.The 50%-70% virus replication is active in the HBV carrier, is chronic viral hepatitis B.Follow-up investigation showed in 5 years, and chronic viral hepatitis B patient liver cirrhosis incidence rate is 2%-20%, and the compensatory liver cirrhosis develops into and loses the compensatory liver cirrhosis is 20%-23%, develops into the 6%-15% that accounts for of hepatocarcinoma.Therefore, primary disease is one of the most serious disease of current harm people ' s health.
The medicine for the treatment of at present chronic hepatitis B clinically mainly contains nucleoside medicines such as alpha-interferon and lamivudine, ganciclovir.Interferon-alpha (IFN-α) once once had been considered to unique effective antiviral therapy medicine, it is better reactive than short patient for the non-hardening and the course of disease, and for most of chronic hepatitis B patients, recur after the drug withdrawal, general effect is disappointing, and in addition, the interferon-' alpha ' price is expensive, and can cause the side effect of the similar flu sample of many patients, even serious adverse more; Nucleoside medicine such as lamivudine, ganciclovir has very strong anti-HBV effect, but life-time service produces drug resistance, particularly lamivudine, can produce serious bounce-back after the drug withdrawal, and explosive jaundice takes place easily.Therefore, efficient, the low toxicity of development, inexpensive chronic hepatitis B medicine have important society, economic worth.
The Calculus Bovis from Northwest of China total glycosides is to separate the effective site that obtains from goatweed Rhizoma Picrorhizae Picrorhiza scrophulariifloraPennell rhizome, has stronger anti-hepatitis virus, liver injury protection activity.
The main component of Calculus Bovis from Northwest of China total glycosides is picroside-II, picroside-I etc., and wherein picroside-II content is more than 70%, and the structure of picroside-II, picroside-I is respectively:
Summary of the invention
The invention provides ethanol extraction of Chinese medicine Rhizoma Picrorhizae and preparation method thereof, the content of Picroside II Amphicoside 6-Vanilloylcatalpol is no less than 70.0% in the described extract; Described extract has the anti-hepatitis virus isoreactivity.
Definite, the invention provides:
1, the preparation method of Chinese medicine Rhizoma Picrorhizae extract is characterized in that the Rhizoma Picrorhizae ethanol extraction is obtained Rhizoma Picrorhizae extract behind the purification, and the content of Picroside II Amphicoside 6-Vanilloylcatalpol is no less than 70.0% in the described extract;
2,1 method is characterized in that:
(1) with the Rhizoma Picrorhizae ethanol percolate extraction of concentration more than 80%;
(2) concentrated extracting solution, last macroporous resin chromatography, use successively distilled water, 20% ethanol,
95% ethanol elution is collected 20% ethanol elution part, concentrates drying;
(3) dry thing is dissolved in acetone, filters, be evaporated to the extractum shape;
3, by the resulting Rhizoma Picrorhizae extract of 1 or 2 method;
4, the purposes of 3 Rhizoma Picrorhizae extract in the medicine of preparation treatment hepatitis B, pulmonary fibrosis;
5, the medicine of treatment hepatitis B, pulmonary fibrosis comprises 3 extract as active component and pharmaceutically acceptable carrier;
6,5 medicine, its dosage form are injection.
By Picroside II Amphicoside 6-Vanilloylcatalpol content height, the good stability of Rhizoma Picrorhizae extract provided by the present invention, anti-hepatitis virus isoreactivity with excellence.
1 quality standard research
1.1 the finger printing of Rhizoma Picrorhizae medical material
According to high performance liquid chromatography (one one of the Pharmacopoeia of the People's Republic of China, appendix VI D), require to measure in conjunction with finger printing.
Chromatographic condition and system suitability test use octadecylsilane chemically bonded silica as filler; With mobile phase A: methanol, Mobile phase B: the 0.3Mmol/L glacial acetic acid solution, according to the form below carries out gradient elution; Flow velocity: 1.0ml/min; DIONEX P680 pump, the PDA-100 diode array detector; Column temperature: 25 ℃.Theoretical cam curve is calculated by the Picroside II Amphicoside 6-Vanilloylcatalpol peak should be not less than 10,000.
| Time (minute) | A(％) | B(％) |
| 0 20 45 60 | 10 30 35 40 | 90 70 65 60 |
The Picroside II Amphicoside 6-Vanilloylcatalpol reference substance is got in the preparation of object of reference solution, accurate claims surely, dissolves and is diluted to the solution that contains 200 μ g among every 1mL with methanol-water (1: 9), promptly.
After the preparation Rhizoma Picrorhizae medicinal material drying of need testing solution is pulverized, cross 14 mesh sieves, material powder 10g gets it filled, the accurate title, decide, and soaks 3h, percolation with 80% ethanol 50mL, collect the 240mL percolate, be concentrated into 100mL, standardize solution is got 1.0ml, with water dilution and standardize solution in the 100ml measuring bottle, filter with microporous filter membrane (0.45 μ m), get subsequent filtrate, promptly.
Accurate respectively object of reference solution and each the 10 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, record 1h chromatograph.12 characteristic peaks should be arranged.
Relative retention time/min (characteristic peak sequence number) 0.2564 ± 10% (1), 0.3664 ± 10% (2), 0.4546 ± 10% (3), 0.5631 ± 10% (4), 0.6886 ± 10% (5), 0.8607 ± 10% (6), 0.8951 ± 10% (7), 1.0000 (8[S]), 1.1647 ± 10% (9), 1.4181 ± 10% (10), 1.4982 ± 10% (11), 1.6375 ± 10% (12)
The collection of illustrative plates of non-total peak area Rhizoma Picrorhizae medical material test sample and finger printing compare, and the non-total peak gross area must not be greater than 10% of total peak area.
Test sample finger printing and reference fingerprint relatively calculate through " the chromatographic fingerprints of Chinese materia medica similarity evaluation 2004A of system version " (Chinese Pharmacopoeia Commission), and similarity should be greater than 0.9.
1.2 half-finished quality standard research
1.2.1 differentiate and adopt thin layer chromatography retention method to differentiate.
Get this product, add methanol and make the solution that contains 5mg among every 1mL approximately, as need testing solution.It is an amount of that other gets the Picroside II Amphicoside 6-Vanilloylcatalpol reference substance, adds methanol and make the solution that contains 5mg among every 1mL approximately, in contrast product solution.According to thin layer chromatography (2000 editions appendix VIB of Chinese Pharmacopoeia) test, draw each 2 μ L of above-mentioned two kinds of solution, put respectively on the silica gel H lamellae, be developing solvent with chloroform-methanol (7: 3), after the expansion, taking-up is dried, and puts under the ultra-violet lamp and inspects.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
1.2.2 check
It is an amount of that clarity is got this product, checks according to the regulation of " clarity test detailed rules and regulations and criterion ", should be up to specification.
It is an amount of that particulate matter is got this product, adds water and make the solution that contains 1mg among every 1mL approximately, and water is cooked blank, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 R microscopic counting), should be up to specification. in accordance with the law
PH value is got this product, adds water and makes the solution that every 1ml contains 5mg, measure (" an appendix VII of Chinese pharmacopoeia version in 2000 G), should be 5.0～7.0. in accordance with the law
Loss on drying is got this product 1.0g, is dried to constant weight at 80 ℃, subtracts weight loss and must not cross 5.0% (" an appendix IX of Chinese pharmacopoeia version in 2000 G).
It is an amount of that solution colour is got this product, adds water and make the solution that contains 5mg among every 1mL approximately, measure (" appendix XI of Chinese pharmacopoeia version in 2000), the color that the test sample pipe presents should be shallower than orange-yellow No. 7 standard color solutions. in accordance with the law
It is an amount of that protein is got this product, adds water and make the solution that contains 5mg among every 1mL approximately, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 S), should be up to specification. in accordance with the law
It is an amount of that tannin is got this product, adds water and make the solution that contains 5mg among every 1mL approximately, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 S), should be up to specification. in accordance with the law
It is an amount of that resin is got this product, adds water and make the solution that contains 5mg among every 1mL approximately, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 S), should be up to specification. in accordance with the law
It is an amount of that oxalates is got this product, adds water and make the solution that contains 5mg among every 1mL approximately, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 S), should be up to specification. in accordance with the law
Residue on ignition is got this product 1.0g, check (" an appendix IX of Chinese pharmacopoeia version in 2000 J), must not cross 0.5%. in accordance with the law
Heavy metal is got the residue that the residue on ignition item is left over, check (" an appendix IX of Chinese pharmacopoeia version in 2000 E second method), contain heavy metal and must not cross 10/1000000ths. in accordance with the law
Arsenic salt is got the residue that the residue on ignition item is left over, check (" an appendix IX of Chinese pharmacopoeia version in 2000 F first method), contain arsenic salt and must not cross 2/1000000ths. in accordance with the law
It is an amount of that potassium ion is got this product, adds water and make the solution that contains 5mg among every 1mL approximately, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 S), should be up to specification. in accordance with the law
The macroporous adsorbent resin residue is measured according to gas chromatography (two appendix VE of Chinese Pharmacopoeia version in 2000).
Chromatographic condition and system suitability test chromatographic column are that Polyethylene Glycol is the crosslinked bonding capillary column (as HP-20M, 25m * 0.32mm * 0.3 μ m) of fixative, and nitrogen is carrier gas; 60 ℃ of initial temperatures rise to 90 ℃ with 3 ℃ of per minutes, rise to 180 ℃ with 50 ℃ of per minutes again, keep 3 minutes.180 ℃ of injector temperatures, 250 ℃ of fid detector temperature.Blank solvent should be noiseless, and the peak-to-peak separating degree of each organic solvent should be up to specification in the reference substance solution.
The algoscopy precision is measured normal hexane 30 μ l, benzene 2.3 μ l, toluene 20 μ l, xylol 20 μ l, o-Dimethylbenzene 20 μ l, styrene 20 μ l, diethylbenzene 20 μ l, puts in the 10ml measuring bottle, adds the DMF dissolving and is diluted to scale, shakes up.Get mixed solution 1.0ml, put in the 50ml measuring bottle, add DMF and be diluted to scale, shake up, get 0.5ml, put in the 10ml measuring bottle, add DMF and be diluted to scale, in contrast product solution.
Other gets the about 1g of this product, and accurate the title decides, and puts in the 10ml measuring bottle, adds the DMF dissolving and is diluted to scale, shakes up, as need testing solution.Get each 2 μ l of reference substance solution and need testing solution respectively, sample introduction is measured in accordance with the law, presses external standard method with calculated by peak area, promptly.
If any solvent peak, its peak area must not be greater than the coordinative solvent peak area in the reference substance solution (the benzene 2ppm that limits the quantity of, normal hexane, toluene, xylol, o-Dimethylbenzene, styrene, diethylbenzene limit the quantity of respectively 20ppm) in the need testing solution.
1.2.3 assay
Picroside II Amphicoside 6-Vanilloylcatalpol photograph high performance liquid chromatography (" an appendix VI of Chinese pharmacopoeia version in 2000 D) measure.
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; With methanol-0.3Mmol/L glacial acetic acid solution (30: 70) is mobile phase; The detection wavelength is 265nm.Number of theoretical plate is pressed the Picroside II Amphicoside 6-Vanilloylcatalpol peak and is calculated, and should be not less than 2000.
It is an amount of that algoscopy is got the Picroside II Amphicoside 6-Vanilloylcatalpol reference substance, and accurate the title decides, and is mixed with the Picroside II Amphicoside 6-Vanilloylcatalpol solution that contains 100 μ g among every 1mL approximately, product solution in contrast with methanol.It is an amount of that other gets the Calculus Bovis from Northwest of China total glycosides, accurate claims surely, adds dissolve with methanol and the solution that every 1mL contains 125 μ g is made in dilution, as need testing solution.Get each 10 μ L of reference substance solution and need testing solution respectively, inject chromatograph of liquid, the record chromatogram is pressed external standard method with calculated by peak area, promptly.
This product is pressed dry product and is calculated, and contains Picroside II Amphicoside 6-Vanilloylcatalpol and must not be less than 70.0%.
Rhizoma Picrorhizae total glucosides is measured according to spectrophotography (2000 editions appendix IV of Chinese Pharmacopoeia A).
It is an amount of that algoscopy is got the Picroside II Amphicoside 6-Vanilloylcatalpol reference substance, and accurate the title decides, and is mixed with the Picroside II Amphicoside 6-Vanilloylcatalpol solution that contains 20 μ g among every 1mL approximately, product solution in contrast with methanol.It is an amount of that other gets the Calculus Bovis from Northwest of China total glycosides, accurate claims surely, adds dissolve with methanol and the solution that every 1mL contains 25 μ g is made in dilution, as need testing solution.According to spectrophotography (2000 editions appendix IV of Chinese Pharmacopoeia A), measure the trap of reference substance solution and need testing solution respectively at the wavelength place of 264nm, calculate with external standard method, both.
This product is pressed dry product and is calculated, and contains Rhizoma Picrorhizae total glucosides in Picroside II Amphicoside 6-Vanilloylcatalpol, should be less than 80.0%.
1.2.4 finger printing
According to high performance liquid chromatography (an appendix VI of Pharmacopoeia of the People's Republic of China D), require to measure in conjunction with finger printing.
Chromatographic condition and system suitability test use octadecylsilane chemically bonded silica as filler; With mobile phase A: methanol, the B:0.3Mmol/L glacial acetic acid solution that flows, flow velocity is 0.8mL/min, according to the form below carries out gradient elution.Theoretical cam curve is calculated by the Picroside II Amphicoside 6-Vanilloylcatalpol peak should be not less than 10,000.
| Time (minute) | A(％) | B(％) |
| 0 20 45 60 | 10 30 35 40 | 90 70 65 60 |
The Picroside II Amphicoside 6-Vanilloylcatalpol reference substance is got in the preparation of object of reference solution, accurate claim fixed, with dissolved in distilled water and be diluted to the solution that contains 200 μ g among every 1ml, promptly.
Injection Calculus Bovis from Northwest of China total glycosides semi-finished product are got in the preparation of need testing solution, accurate claim surely, with dissolved in distilled water and be diluted to the solution that every 1mL contains 200 μ g, filter with microporous filter membrane (0.45 μ m), get subsequent filtrate, promptly.
Accurate respectively object of reference solution and each the 20 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, record 1h chromatograph.6 characteristic peaks should be arranged.
Relative retention time/min (characteristic peak sequence number) 0.3659 ± 10% (1), 0.8600 ± 10% (2), 0.89522 ± 10% (3), 1.0000 (4[S]), 1.1639 ± 10% (5), 1.4158 ± 10% (6).
The collection of illustrative plates of non-total peak area injection Calculus Bovis from Northwest of China total glycosides semi-finished product test sample and finger printing compare, and the non-total peak gross area must not be greater than 10% of total peak area.
Test sample finger printing and reference fingerprint calculate through " the chromatographic fingerprints of Chinese materia medica similarity evaluation 2004A of system version " (Chinese Pharmacopoeia Commission), and similarity should be greater than 0.9.
1.3 the quality standard research of finished product (injection)
1.3.1 differentiate and adopt thin layer chromatography retention method to differentiate.
Get this product, add methanol and make the solution that contains 5mg among every 1mL approximately, as need testing solution.It is an amount of that other gets the Picroside II Amphicoside 6-Vanilloylcatalpol reference substance, adds methanol and make the solution that contains 5mg among every 1mL approximately, in contrast product solution.According to thin layer chromatography (2000 editions appendix VIB of Chinese Pharmacopoeia) test, draw each 2 μ L of above-mentioned two kinds of solution, put respectively on the silica gel H lamellae, with chloroform-methanol (7: 3) is developing solvent, after the expansion, takes out, dry, put under the ultra-violet lamp (254nm) and inspect.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
1.3.2 check
Clarity is operated in super-clean bench.Get 5 of clean tool plug nessler colorimetric tubes, add filterable in advance water for injection 20mL respectively, by " clarity test detailed rules and regulations and criterion " injectable sterile powder item, rotate gently in umbrella basin edge, make solvent form eddy flow, look with visual inspection immediately, write down hair in the bottle, count,, add 1 test sample then respectively as blank, make fully dissolving,, rotate gently or swing in the horizontal observation in umbrella basin edge, look with visual inspection, write down hair, count, deduction is blank, promptly.
This product must not detect the above insoluble foreign body of 500 μ m.Every contained hair and the white point of 200～500 μ m, white piece and color dot sum that is shorter than 500 μ m must not be above 10.
Particulate matter is got the content of 1 bottle of this product, with the 80ml dissolving of purifying waste water, makes blank of purifying waste water, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 R microscopic counting), should be up to specification. in accordance with the law
PH value is got this product, adds water and makes the solution that every 1ml contains 1mg, measure (" an appendix VII of Chinese pharmacopoeia version in 2000 G), should be 5.0～7.0. in accordance with the law
Loss on drying is got this product 1.0g, is dried to constant weight at 80 ℃, subtracts weight loss and must not cross 5.0% (" an appendix IX of Chinese pharmacopoeia version in 2000 G).
It is an amount of that solution colour is got this product, adds water and make the solution that contains 5mg among every 1mL approximately, measure (" appendix XI of Chinese pharmacopoeia version in 2000), the color that the test sample pipe presents should be shallower than orange-yellow No. 7 standard color solutions. in accordance with the law
Protein is got this product 30mg, adds water 10ml and makes dissolving, gets 2ml, puts in the test tube, drips and rubs 1～3 of sour test solution, must not produce muddiness.
Tannin is got this product 30mg, adds water 10ml and makes dissolving, gets 1ml, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 S), should be up to specification. in accordance with the law
Resin is got this product 30mg, adds water 10ml and makes dissolving, gets 5ml, puts in the separatory funnel, adds chloroform 10ml jolting and extracts, measure (" appendix IXS of Chinese pharmacopoeia version in 2000), should be up to specification. in accordance with the law
Oxalates is got this product 30mg, adds water 10ml and makes dissolving, regulates pH value to 1～2 with dilute hydrochloric acid, and insulation elimination precipitation is regulated pH value to 5～6, gets 2ml, adds 2～3 of 3% calcium chloride solutions, places 10 minutes, muddiness or precipitation must not occur.
Heavy metal is got this product 1.0g, check (" an appendix IX of Chinese pharmacopoeia version in 2000 E second method), contain heavy metal and must not cross 10/1000000ths. in accordance with the law
Arsenic salt is got this product 0.40g, add 2% magnesium nitrate alcoholic solution 3ml, light, in the afterburnt, elder generation is with the carbonization that makes of little heated, again 500～600 ℃ of vehement ashing extremely fully, put cold, add hydrochloric acid 5ml and water 21ml makes dissolving, check (" an appendix IX of Chinese pharmacopoeia version in 2000 F first method), arsenic content must not cross 2/1000000ths. in accordance with the law
Potassium ion is got this product 30mg, measure (" an appendix IX of Chinese pharmacopoeia version in 2000 S), should be up to specification. in accordance with the law
Pyrogen is got this product 30mg, adds 0.9% sodium chloride injection 10mL and makes dissolving, and dosage is injected 3mL by the every 1kg body weight of rabbit, check (" an appendix XIII of Chinese pharmacopoeia version in 2000 A), should be up to specification. in accordance with the law
The aseptic this product of getting is an amount of, adds sterilized water for injection and makes the solution that every 1ml contains 5mg, after handling with direct inoculation, check (" appendix XIIIB of Chinese pharmacopoeia version in 2000 does not have under the mattress inspection technique item), should be up to specification. in accordance with the law
Other should meet every regulation relevant under the injection item (" appendix IU of Chinese pharmacopoeia version in 2000).
1.3.3 assay
Picroside II Amphicoside 6-Vanilloylcatalpol photograph high performance liquid chromatography (" an appendix VI of Chinese pharmacopoeia version in 2000 D) measure.
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; With methanol-0.3Mmol/L glacial acetic acid solution (30: 70) is mobile phase; The detection wavelength is 265nm.Number of theoretical plate is pressed the Picroside II Amphicoside 6-Vanilloylcatalpol peak and is calculated, and should be not less than 2000.
It is an amount of that algoscopy is got the Picroside II Amphicoside 6-Vanilloylcatalpol reference substance, and accurate the title decides, and is mixed with the Picroside II Amphicoside 6-Vanilloylcatalpol solution that contains 100 μ g among every 1mL approximately, product solution in contrast with methanol.Other gets " content uniformity " and checks following this product an amount of (being equivalent to Rhizoma Picrorhizae total glucosides 27mg approximately), accurately claims surely, adds dissolve with methanol and dilutes and make the solution that every 1mL contains 120 μ g, as need testing solution.Get each 10 μ L of reference substance solution and need testing solution respectively, inject chromatograph of liquid, the record chromatogram is pressed external standard method with calculated by peak area, promptly.
Rhizoma Picrorhizae total glucosides is measured according to spectrophotography (2000 editions appendix IV of Chinese Pharmacopoeia A).
It is an amount of that algoscopy is got the Picroside II Amphicoside 6-Vanilloylcatalpol reference substance, and accurate the title decides, and is mixed with the solution that contains 20 μ g among every 1mL approximately with methanol, in contrast product solution.Other gets " content uniformity " and checks following this product an amount of (being equivalent to Rhizoma Picrorhizae total glucosides 27mg approximately), accurately claims surely, adds dissolve with methanol and dilutes and make the solution that every 1mL contains 25 μ g, as need testing solution.According to spectrophotography (2000 editions appendix IV of Chinese Pharmacopoeia A), measure the trap of reference substance solution and need testing solution respectively at the wavelength place of 264nm, calculate with external standard method, both.
This product contains picroside-II for every bottle must not be lower than 21mg, contains total glycosides and should be 27mg in picroside-II.
1.3.4 finger printing
According to high performance liquid chromatography (an appendix VI of Pharmacopoeia of the People's Republic of China D), require to measure in conjunction with finger printing.
Chromatographic condition and system suitability test use octadecylsilane chemically bonded silica as filler; With mobile phase A: methanol, Mobile phase B: the 0.3Mmol/L glacial acetic acid solution, according to the form below carries out gradient elution; Flow velocity: 1.0ml/min; The detection wavelength is 265nm.Theoretical cam curve is calculated by the Picroside II Amphicoside 6-Vanilloylcatalpol peak should be not less than 10,000.
| Time (minute) | A(％) | B(％) |
| 0 20 45 60 | 10 30 35 40 | 90 70 65 60 |
The Picroside II Amphicoside 6-Vanilloylcatalpol reference substance is got in the preparation of object of reference solution, accurate claims surely, dissolves and is diluted to the solution that contains 200 μ g among every 1mL with methanol-water (1: 9), promptly.
Injection Calculus Bovis from Northwest of China total glycosides is got in the preparation of need testing solution, accurate claims surely, dissolves and is diluted to the solution that every 1mL contains 200 μ g with methanol-water (1: 9), with microporous filter membrane (0.45 μ m) filtration, gets subsequent filtrate, promptly.
Accurate respectively object of reference solution and each the 20 μ l of need testing solution of drawing of algoscopy inject chromatograph of liquid, record 1h chromatograph.5 characteristic peaks should be arranged.
Relative retention time/min (characteristic peak sequence number) 0.3671 ± 10% (1), 0.8593 ± 10% (2), 0.8949 ± 10% (3), 1.0000 (4[S]), 1.4140 ± 10% (5)
The collection of illustrative plates of non-total peak area injection Calculus Bovis from Northwest of China total glycosides test sample and finger printing compare, and the non-total peak gross area must not be greater than 10% of total peak area.
Test sample finger printing and reference fingerprint calculate through " the chromatographic fingerprints of Chinese materia medica similarity evaluation 2004A of system version " (Chinese Pharmacopoeia Commission), and similarity should be greater than 0.9.
2 preliminarily stabilised testing datas
2.1 half-finished preliminarily stabilised testing data
This product is 60 ℃ of high temperature, in the strong illumination test, and uncovered placement 10 days, appearance character, clarity, pH, assay not have variation substantially.Under humidity 75% (25 ℃) and 92.5% (25 ℃), examination in ten days has certain deliquescence, and then causes the loss on drying value of sample to increase and the content minimizing.
This product is enclosed within the packing, in 40 ℃ of temperature, under relative humidity 75% condition, examines 6 months, and appearance character, clarity, loss on drying and content do not have to change substantially.This product is enclosed within the packing, places 6 months in room temperature, and its appearance character, clarity, loss on drying and content do not have to change substantially.
Above stability assessment shows that this product should seal when storing, and prevents the deliquescence of water in air branch to it.The operating period of this product is tentative to be 2 years.
According to above study on the stability result, the effect duration that can tentatively work out this product is 2 years.
2.2 the preliminarily stabilised testing data of finished product
Get this product, remove outer packing box, put into the exsiccator (RH75%) of NaCl saturated solution, and place in the constant temperature oven, temperature is under 40 ± 2 ℃ of conditions, carries out accelerated stability test.Placing temperature is that 25 ℃ ± 2 ℃, humidity are under 60% ± 10% the condition, to carry out long-term stable experiment.
This product was placed 6 months in long term test placement 6 months and accelerated test under commercially available back, stable in properties, and its appearance character, clarity, pH value, content etc. are not seen obvious change, other project is not seen influence yet.According to above study on the stability result, the effect duration that can tentatively work out this product is 2 years.
According to above study on the stability result, the effect duration that can tentatively work out this product is 2 years.
Because of this product is the lyophilized injectable powder that raw material is made with the total glycosides that extracts the purification gained from Rhizoma Picrorhizae, there is not other active substance, do not use adjuvant.So pharmaceutical research adopts the raw material administration.
3 pharmacodynamic studies
3.1 carbon tetrachloride is caused the prevention protective effect research of chmice acute hepatic injury
Adopt lumbar injection 0.2%CCl
4Peanut oil solution 0.1ml/10g causes the acute liver damage model, detects the value of serum transaminase ALT, AST.Experimental result shows, Calculus Bovis from Northwest of China total glycosides little (4mg/kg), in (8mg/kg), big (16mg/kg) three dosage groups can obviously reduce CCl
4The ALT that causes, AST raise, and compare with model control group, and learning by statistics to handle has significant difference or highly significant or utmost point significant difference (P＜0.05, P＜0.01 or P＜0.001); Positive controls ALT, AST also obviously reduce, and learn by statistics and handle, and utmost point significant difference (P＜0.001) is arranged.Show that the Calculus Bovis from Northwest of China total glycosides is to mice CCl
4Acute liver damage has the better protect effect.
3.2 the Calculus Bovis from Northwest of China total glycosides causes the prevention protective effect research of rat chronic hepatic injury to carbon tetrachloride
Adopt subcutaneous injection 25%CCl
4Peanut oil solution 5ml/kg, 2 times weekly, in totally 3 weeks, cause the chronic hepatic injury model, preceding 3 days of modeling is intravenous injection Calculus Bovis from Northwest of China total glycosides and positive control Yinzhihuang Injection in advance, every day 1 time, 3 weeks of successive administration.1h gets blood and surveys serum AST, ALT, TP and ALB after the last administration, and the execution animal is got liver and does histopathologic examination, observes it to CCl
4Due to the pre-protective effect of chronic liver dysfunction.Result of the test shows: Calculus Bovis from Northwest of China total glycosides little (3mg/kg), in (6mg/kg), heavy dose of group (12mg/kg) compare with model group, can significantly reduce CCl
4Serum AST, the ALT that causes raises, and significantly suppresses CCl
4Total serum protein that causes (TP) and albumin (ALB) reduce, credit is analysed by statistics, all have very or utmost point significant difference (P＜0.01 or P＜0.001), the effect that is subjected to the reagent thing to have rising of remarkable inhibition serum transaminase and total serum protein and albumin to reduce is described; Positive controls is compared with model group, and serum AST, ALT all have significance to reduce (P＜0.01), and total serum protein (TP) and albumin (ALB) also all have remarkable rising (P＜0.01).
3.3 the Calculus Bovis from Northwest of China total glycosides is to the therapeutical effect research of rat chronic hepatic injury due to the carbon tetrachloride
Adopt subcutaneous injection 25%CCl
4Peanut oil solution 2ml/kg, secondary in continuous 6 weeks, causes the chronic hepatic injury model weekly.After 2 weeks of modeling, get blood behind the socket of the eye and survey Serum ALT and AST, according to Serum ALT and AST value, divide into groups with reference to body weight: model contrast, positive control, Calculus Bovis from Northwest of China total glycosides little (3mg/kg), in (6mg/kg) and (12mg/kg) dosage group greatly.Each administration group tail vein injection administration, model contrast and normal control group give the equal-volume normal saline, once a day, continuous 4 weeks.After 24 hours, get blood in the last administration, survey Serum ALT, AST, TP, ALB, get liver and do histopathologic examination and measure hydroxyproline and glycogen initial value.Result of the test shows: the Calculus Bovis from Northwest of China total glycosides can significantly reduce CCl
4Cause the level of rat chronic hepatic injury serum transaminase (AST, ALT), rising total serum protein (TP) and albumin (ALB) level also can reduce hydroxyproline and rising hepatic glycogen content, and the visible liver cirrhosis of hepatic pathology histological examination obviously alleviates.Prompting Calculus Bovis from Northwest of China total glycosides causes the experimental rat chronic hepatic injury to carbon tetrachloride certain therapeutical effect.
3.4 to the excretory influence of rat bile
Adopt the biliary drainage method to detect the Calculus Bovis from Northwest of China total glycosides to the excretory influence of rat bile.The result shows that three dosage groups of Calculus Bovis from Northwest of China total glycosides (3mg/kg, 6mg/kg, 12mg/kg) have tangible choleretic effect.After administration, with the comparison of blank group low dose behind 60min, middle and high dosage all has significant differences (P＜0.01) from 30-120min, at 0.5-2.0h significant difference (P＜0.05 or P＜0.01), the sustainable 2h of choleretic effect are arranged with comparison before the self administration.Yinzhihuang Injection also has tangible choleretic effect, and its choleretic effect is the most obvious when 30min.
3.5 injection Calculus Bovis from Northwest of China total glycosides is to the influence of mice non-specific immunity
Adopt the carbon clearance method to detect of the influence of injection Calculus Bovis from Northwest of China total glycosides to mice reticuloendothelial system phagocytic function.The result shows: three dosage groups of Calculus Bovis from Northwest of China total glycosides and Yinzhihuang Injection carbon clearance index K, phagocytic index α all are significantly increased; Calculus Bovis from Northwest of China total glycosides high dose thymus index and blank group relatively have significant difference (P＜0.05).
3.6 injection Calculus Bovis from Northwest of China total glycosides causes the prevention protective effect of chmice acute hepatic injury to D-Gal
Adopt Kunming mouse lumbar injection D-Gal solution 800mg/kg, cause the acute liver damage model, detect the value of serum transaminase ALT, AST.Experimental result shows, mice serum ALT, AST obviously raise after the D-Gal hepatic injury, and each dosage of Calculus Bovis from Northwest of China total glycosides all makes the Serum ALT of rising, AST significantly reduce, and compares with model control group, and learning by statistics to handle has significant difference or highly significant (P＜0.05, P＜0.01); But positive control drug Yinzhihuang Injection also highly significant reduces Serum ALT, AST (P＜0.01), and middle dosage group is suitable with the positive controls effect; The effect of high dose group liver injury protection is better than the positive control Yinzhihuang Injection.
3.7 injection Calculus Bovis from Northwest of China total glycosides is to the therapeutical effect of rat chronic hepatic injury due to the D-Gal
Adopt lumbar injection D-Gal solution 400mg/kg, secondary in continuous 6 weeks, causes the chronic hepatic injury model weekly.After 2 weeks of modeling, get blood behind the socket of the eye and survey Serum ALT and AST, according to Serum ALT and AST value, divide into groups with reference to body weight: model contrast, positive control, Calculus Bovis from Northwest of China total glycosides little (3mg/kg), in (6mg/kg) and (12mg/kg) dosage group greatly.Each administration group tail vein injection administration, model contrast and normal control group give the equal-volume normal saline, once a day, continuous 4 weeks.After 24 hours, get blood in the last administration, survey Serum ALT, AST, TP, ALB, get liver and do histopathologic examination and measure hydroxyproline and glycogen initial value.Result of the test shows: the Calculus Bovis from Northwest of China total glycosides can significantly reduce the level that D-Gal causes rat chronic hepatic injury serum transaminase (AST, ALT), rising total serum protein (TP) and albumin (ALB) level, also can reduce hydroxyproline and rising hepatic glycogen content, the visible liver cirrhosis of hepatic pathology histological examination obviously alleviates.Prompting Calculus Bovis from Northwest of China total glycosides causes the experimental rat chronic hepatic injury to D-Gal certain therapeutical effect.
3.8 anti-HBV effect in the injection Calculus Bovis from Northwest of China total glycosides body
Adopt the positive Sanguis Anas domestica of duck shin intravenous injection 0.2ml Shanghai sheldrake DHBV-DNA clear, cause the DHB model, detect serum DHBV-DNA content.Three batches of experimental results show, injection Calculus Bovis from Northwest of China total glycosides height (120mg/kg), in (60mg/kg), low (30mg/kg) three dosage groups can reduce DHBV-DNA content in the DHBV-DNA infected duck serum.Compare with model control group, learning by statistics to handle has significant difference (P＜0.05 or P＜0.01); Positive drug control group DHBV-DNA also obviously reduces.Injection Calculus Bovis from Northwest of China total glycosides has therapeutical effect preferably to the DHBV-DNA infected duck.
3.9 the external anti-HBV effect research of injection Calculus Bovis from Northwest of China total glycosides
In the maximal non-toxic concentration range of injection Calculus Bovis from Northwest of China total glycosides, added 2.2.15 cell co-cultivation 8 days with the DMEM culture medium that contains injection Calculus Bovis from Northwest of China total glycosides 500,250,125,62.5,31.25 μ g/ml to the 2.2.15 cell.Put experimental techniques such as the method for exempting from, dot blot hybridization and Southernblot by employing, the effect situation that detection of drugs is expressed 2.2.15 cell surface antigen, e antigen product, and observe the extremely degree of duplicating of HBV-DNA in the pastille culture fluid of 2.2.15 cell respectively.The result shows: the 2.2.15 cell HBsAg, the HBeAg value that contain the cultivation of injection Calculus Bovis from Northwest of China total glycosides pharmaceutical culture medium are lower than the blank group, and the HBV-DNA carrying capacity is lower than the cell matched group in cell conditioned medium liquid and the cell.Prove that it has good anti-hepatitis B activity.
3.10 therapeutical effect to experimental pulmonary fibrosis
Idiopathic pulmonary interstitial fibrosis (Idiopathic pulmonary fibrosis, IPF) be the not bright interstitial lung disease of a kind of reason, lung tissue disease's Neo-Confucianism show as the homeliness type interstitial pneumonia (usual interstitial pneumonia, UIP), the pathogeny complexity.Pulmonary fibrosis is that atypical pneumonia (SARS) important clinical refers to one of disease, and disease patients such as pulmonary tuberculosis, pulmonary's radiotherapy all have the clinical manifestation of pulmonary fibrosis, still do not have effective treatment means at present.Inject bleomycin through trachea and cause Pulmonary Fibrosis in Rats, its pathological process is similar to human IPF, is widely used as the classical animal model of pulmonary fibrosis.
3.10.1 materials and methods
3.10.1.1 80 of animal and reagent SD secondary rats, ♂ ♀ half and half, body weight 200 ± 20g (department of the Chinese Academy of Sciences of Department Of Medicine, Peking University's laboratory animal section, credit number: SCXK (capital) 2002-0001), laboratory animal occupancy permit number: SYXK11-00-0025.Animal was tested after conforming 3.(Bleomycin, BLMA5): lot number 02010201, pharmaceutical Co. Ltd is won in Harbin to bleomycin.
3.10.1.2 experimental technique
3.10.1.2.1 animal model duplicate conventional anesthetized rat, it is lain on the back be fixed on the rat experiment platform, cut skin of neck, separate trachea, slowly inject BLMA55mg/kg with the 1ml syringe, the upright and rotation with rat makes medicine uniform distribution in lung after the injection, thereafter skin suture is put laboratory observation.The blank group is operated with method, injects normal saline 1ml/kg.
3.10.1.2.2 experiment grouping postoperative the 3rd day, rat figure, diet, feces are normal, and wound surface does not have infection.Animal pattern is divided into 3 groups at random: model control group, high dose administration group, low dosage administration group, 20 of every group of rats, ♂ ♀ half and half, ♂ ♀ sub-cage rearing, 5 in every cage.20 of blank group rats are operated with method.
3.10.1.2.3 medication blank group, model control group are irritated stomach respectively and are given normal saline 2ml200g-1; High and low dose administration group is irritated stomach respectively and is given the equal-volume medicinal liquid, once a day, and continuous 28 days.
3.10.1.2.4 sample process etherization rat, sacrificed by decapitation, complete separation trachea and lung, record is also observed.Get rat left side lung be soaked in the 10% neutral formalin solution fixing, conventional section, HE dyeing is observed hepatocellular histopathology and is changed under light microscopic.According to the injury of lung grading: 1. lung configuration: two lung pinkiness, smooth surface, elasticity are well remembered 0 fen; Two lungs are dispersed in petechial hemorrhage note 1 minute; Two lungs are seen intensive petechial hemorrhage, kitchen range shape ecchymosis, and lung volume increased note 2 minutes; Two lung canescence, part see that the nodal-like that differs in size changes, and still have outmoded petechia note 3 minutes; Two lungs are pale, volume-diminished, and hardness increases, and surperficial nodal-like changes and streak chase is remembered 4 fens.2. om observation: the control rats lung structure is clear, note 0 minute occurs obviously changing; The slight edema of alveolar septum has more macrophage (AM) and neutrophilic granulocyte (PMN) to soak into note 1 minute in the alveolar space; Visible a large amount of inflammatory cell infiltrations based on AM and PMN are remembered 2 fens in the obvious edema of alveolar septum, alveolar space; It is thick that alveolar septum increases the back, is main cellular infiltration with AM, lymphocyte (LYM), and fibroblast is increased in the matter, intralesional alveolar atrophy note 3 minutes; The obvious broadening of alveolar septum, fibroblast and collagen stroma showed increased note 4 minutes; Alveolar structure destroys, and alveolar wall significantly thickens, interstitial pulmonary fibrosis cicatrization, the inaccessible note of capillary lumen 5 minutes.
3.10.1.3 test data adopts SPSS10.0 software to carry out statistical analysis
3.10.2 result
Be canescence 3.10.2.1 the lung configuration is observed the two lungs of visible model control group rat, the surface sees that the nodal-like that differs in size changes, and hardness increases.Two groups of all visible obviously improvement of administration, P＜0.01 sees Table 1.
3.10.2.2 the obvious broadening of the visible model control group alveolar septum of om observation, fibroblast and collagen stroma showed increased, the part alveolar structure destroys, and alveolar wall significantly thickens.Two groups of all visible obviously improvement of administration, see the following form in P＜0.01.
| Group | The lung configuration | Om observation | |||||||||
| 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 5 | |
| The blank group | 18 | 2 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 0 | 0 |
| Model control group | 0 | 0 | 0 | 11 | 9 | 0 | 0 | 0 | 3 | 12 | 5 |
| Low dosage administration group ** | 5 | 9 | 6 | 0 | 0 | 0 | 6 | 11 | 3 | 0 | 0 |
| High dose administration group ** | 10 | 8 | 2 | 0 | 0 | 0 | 10 | 9 | 1 | 0 | 0 |
* and model group be P＜0.01 relatively,
The research of 4 general pharmacologies
With ICR mice, SD rat injection Calculus Bovis from Northwest of China total glycosides has been carried out general pharmacology and learned research, mainly observed injection Calculus Bovis from Northwest of China total glycosides the unify influence of respiratory system of nervous system, cardiovascular system.The result shows, injection Calculus Bovis from Northwest of China total glycosides with 60mg/kg, 180mg/kg and 600mg/kg intravenous administration after, general behavior activity, coordination exercise and sub-threshold dose pentobarbital sodium syngignoscism to mice in 3 hours do not have obvious influence.Injection Calculus Bovis from Northwest of China total glycosides with 30mg/kg, 90mg/kg and 300mg/kg intravenous administration after, in 3 hours, the inquiry activity of rat (the center lattice time of staying, hold up and modify number of times) is not had obviously influence; There is not obvious influence to walking number of times between the rat grid.Injection Calculus Bovis from Northwest of China total glycosides with 30mg/kg, 90mg/kg and 300mg/kg intravenous administration after, in 4 hours, anesthetized rat cardiovascular system (blood pressure, heart rate, the rhythm of the heart, electrocardiogram) and respiratory system (respiratory frequency, respiratory rhythm, amplitude of respiration) there is not obviously influence.Results suggest, injection Calculus Bovis from Northwest of China total glycosides are pressed when recommending the administration of human body clinical dosage, and nerve system of human body, blood circulation and respiratory system are not all had obvious influence.
5 acute toxicity tests
Adopt ICR mice, SD rat that the Calculus Bovis from Northwest of China total glycosides is carried out acute toxicity test, investigate the Calculus Bovis from Northwest of China total glycosides to mice single tail vein injection, to rat single tail vein injection administration median lethal dose(LD 50) (LD
50).Mouse tail vein injection gives the LD of Calculus Bovis from Northwest of China total glycosides
50Be the 1563.8mg/kg body weight, be equivalent to 3127 times of referrer's clinical dosage 0.5mg/kg body weight.The rat tail vein injection gives the LD of Calculus Bovis from Northwest of China total glycosides
50Be the 963.4mg/kg body weight, be equivalent to 1927 times of referrer's clinical dosage 0.5mg/kg body weight for humans.
6 long term toxicity tests
According to " study of tcm new drug guide ", the requirement of relevant documents such as " provisions for new drugs approval---about the revision and the supplementary provisions of Chinese medicine part ", injection Calculus Bovis from Northwest of China total glycosides is carried out the rat long term toxicity test, observe and give rats by intraperitoneal injection 3 months, the toxic reaction that Beagle dog intravenous drip Calculus Bovis from Northwest of China total glycosides produced body owing to cumulative action after 3 months, be provided at the target organ and the degree of injury thereof that occur toxicity under the high dose administration situation, understand the delayed response and the reversibility of toxic action, determine non-toxic reaction dosage, provide reference for drafting the human safe dose.
Get about 6 age in week SD rat, healthy Beagle dog each be divided into four groups at random, establish large, medium and small dosage group and matched group, basic, normal, high dosage of rat and control rats respectively are 30,6 every group of Beagle dogs, male and female half and half.The heavy dose of group of SD rat presses that 300mg/kg body weight, middle dosage group are pressed the 90mg/kg body weight, small dose group is pressed the administration of 30mg/kg body weight, and matched group waits the capacity normal saline.Rat administration 6 days weekly, drug withdrawal 1 day, successive administration 3 months is observed general situation every day, measures body weight and food-intake weekly, respectively gets the part animal after 1 month in administration 3 months and drug withdrawal and does to check comprehensively.The large, medium and small dosage of the administration of Beagle dog is respectively 50,15 and 5mgkg
-1D
-1The administration 6 days weekly of Beagle dog, drug withdrawal 1 day, successive administration 3 months was observed for 2 weeks after the drug withdrawal, observed the index that detects and comprised general signs, appetite, body weight, hematological indices, blood parameters, organ weights and organ coefficient, pathological examination.
The result shows that matched group and each medication group rat are movable from start to finish normal, well-grown, and appetite is normal.All do not find to be the ANOMALOUS VARIATIONS of dosage correlation with medicine at aspects such as hematology, routine urinalysis, blood parameters and pathologic findings; Each dosage treated animal of pathological examination is not all found and the form pathological change of medicine related organization.Beagle dog administration 3 months, each administration group Beagle dog diet, movable normal, no overt toxicity reaction; Appetite, body weight and blank group Beagle dog ratio, no significant difference; Blood parameters of each administration group Beagle dog and hematological indices and blank group Beagle dog ratio, there were significant differences for part index number, but change little, and all in normal range, irrelevant with administration.
The 7 specific safety tests relevant with the whole body administration
Requirement according to relevant documents such as " study of tcm new drug guide ", " provisions for new drugs approval---about the revision and the supplementary provisions of Chinese medicine part ", observe the zest of injection Calculus Bovis from Northwest of China total glycosides intravenous administration to blood vessel, adopt fresh Sanguis Leporis seu oryctolagi that injection Calculus Bovis from Northwest of China total glycosides is carried out the hemolytic experiment, adopt the Cavia porcellus intravenous administration to carry out hypersensitive test, adopt Cavia porcellus to carry out passive cutaneous anaphylaxis test, for clinical rational drug use provides foundation.The result shows, rabbit auricular vein injected dose is the Calculus Bovis from Northwest of China total glycosides of 10mg/kg, 30mg/kg, after the each administration in injection site, no significant change, do not see situations such as hyperemia, redness, pathological observation shows that it is checked substantially and there is no unusually, do not see to have and significantly organize hemorrhage, downright bad phenomenon that each organizational structure is intact; Add the Calculus Bovis from Northwest of China total glycosides in the fresh Sanguis Leporis seu oryctolagi and haemolysis and red blood cell condensation did not occur in 2 hours, injection Calculus Bovis from Northwest of China total glycosides hemolytic reaction is judged to feminine gender; The anaphylaxis of Cavia porcellus intravenous administration 30mg/kg Calculus Bovis from Northwest of China total glycosides is negative; Intravenous injection 30mg/kg Calculus Bovis from Northwest of China total glycosides does not cause the Cavia porcellus passive cutaneous anaphylaxis, PCA.Show that test dose Calculus Bovis from Northwest of China total glycosides intravenous administration does not have tangible blood vessel irritation, no haemolysis, intravenous administration do not cause systemic anaphylaxis, do not cause passive cutaneous anaphylaxis, PCA yet.
This product is the injection freeze-dried powder, and every bottle contains injection Calculus Bovis from Northwest of China total glycosides semi-finished product 30mg (total glycosides is in picroside-II 24mg), is used for the treatment of chronic hepatitis B.Intravenous drip is faced with preceding with distilled water for injection dissolving, recommends usage and consumption to be: 1 time on the one, one time 1～2 bottle, with slowly instillation after 5～10% glucose injections, 250～500mL dilution; Diabetics uses with 0.9% physiologic saline for substitute glucose injection dilution back.
The specific embodiment
The Rhizoma Picrorhizae pulverizing medicinal materials is become coarse powder, and (solvent volume: medical material weight) infiltration percolation extraction after 6 hours, percolation speed was 1.2BV/h, collected 24 times of amount percolates, was extracting solution in 5: 1 with 80% ethanol.It is 1: 1 (medical material weight: liquor capacity) to concentration that extracting solution is used rotating thin film concentrating instrument (rotating thin film concentrating instrument (2L), R205B type go up marine living Science and Technology Ltd. and produce) concentrating under reduced pressure; Concentrated solution filters, and filtrate is the upper prop sample liquid.Sample liquid is pressed the 0.6BV applied sample amount feed ZTC-1 type macroporous resin column (ZTC-1 type macroporous resin, Nankai University's development, Tianjin became the production of clarification technique company limited in positive day) in, use the distilled water of 12BV, 20% ethanol of 12BV, 95% ethanol elution of 8BV successively, collect 20% ethanol elution part, concentrating under reduced pressure, vacuum drying is also pulverized; Powder is measured acetone solutions with 2 times, and jolting limit in limit slowly adds 8 times of amount acetone again, filters, and filtrate decompression is reclaimed solvent to the extractum shape, and vacuum drying is also pulverized, and gets faint yellow crystalloid powder, is injection Calculus Bovis from Northwest of China total glycosides semi-finished product.
Semi-finished product are buff powder, and odorless has hygroscopicity.Easily molten in methanol, in water, dissolve, insoluble in ether, chloroform.
To injection Calculus Bovis from Northwest of China total glycosides semi-finished product, average total yield is more than 3.0% to this technology from medical material, and total glycosides content is more than 80% in the finished product.This technology is applicable to separation and purification injection Calculus Bovis from Northwest of China total glycosides semi-finished product from the Rhizoma Picrorhizae medical material, has advantages such as stable, quick, the high yield of finished product.
The preparation prescription of injection Calculus Bovis from Northwest of China total glycosides is as follows:
Injection Calculus Bovis from Northwest of China total glycosides semi-finished product 30g
Water for injection adds to 1000ml
Make 1000 bottles altogether
Take by weighing recipe quantity Calculus Bovis from Northwest of China total glycosides by above prescription, add an amount of water for injection, stir and make its dissolving; Add to the full amount of water for injection; Add 0.1% needle-use activated carbon of amount of liquid, fully stirred 30 minutes; Decarbonization filtering; With 0.22 μ m filtering with microporous membrane; Plug is partly rolled in fill; Lyophilization, lid is rolled in tamponade.Each detects index (as uniformity of dosage units, content uniformity etc.) and all meets pharmacopeia regulation, and accelerated stability test shows, preparation was placed 6 months under 40 ℃, 75% relative humidity condition, at room temperature placed 6 months, had good stability.
Finished product content outward appearance is a pale yellow powder, and is easily molten in water.
Claims (2)
1, the purposes of Rhizoma Picrorhizae extract in the medicine of preparation treatment pulmonary fibrosis, the content of Picroside II Amphicoside 6-Vanilloylcatalpol is no less than 70.0% in the wherein said Rhizoma Picrorhizae extract.
2, purposes as claimed in claim 1, described Rhizoma Picrorhizae extract are injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100114874A CN1325079C (en) | 2005-03-28 | 2005-03-28 | Chinese medicine picrorhiza extract possessing anti hepatitis B virus activity and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100114874A CN1325079C (en) | 2005-03-28 | 2005-03-28 | Chinese medicine picrorhiza extract possessing anti hepatitis B virus activity and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686201A CN1686201A (en) | 2005-10-26 |
| CN1325079C true CN1325079C (en) | 2007-07-11 |
Family
ID=35304243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100114874A Expired - Fee Related CN1325079C (en) | 2005-03-28 | 2005-03-28 | Chinese medicine picrorhiza extract possessing anti hepatitis B virus activity and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1325079C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002786B (en) * | 2006-01-17 | 2010-06-02 | 周亚伟 | Plaster for treating hepatitis B, and its preparing method |
| CN101040953B (en) * | 2006-03-20 | 2011-07-20 | 周亚伟 | Injection for treating hepatitis and its preparing process |
| CN102942609A (en) * | 2012-11-23 | 2013-02-27 | 济南康众医药科技开发有限公司 | Method for preparing extract with over 50% of picrorhiza saponin II |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1298705A (en) * | 2000-12-19 | 2001-06-13 | 吉林省力源药业股份有限公司 | Chinese medicine for treating hepatitis B and its preparing process |
| CN1488637A (en) * | 2003-09-05 | 2004-04-14 | 北京深文医药科技开发有限公司 | Method for preparing total aglycone extract of radix picrorrhizae |
| CN1498892A (en) * | 2002-11-05 | 2004-05-26 | 维京仲华（上海）生物医药科技有限公 | Extract of general glycoside in picrorhiza rhizome as well as preparation method and application |
| CN1590396A (en) * | 2003-09-05 | 2005-03-09 | 天津药物研究院 | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method |
-
2005
- 2005-03-28 CN CNB2005100114874A patent/CN1325079C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1298705A (en) * | 2000-12-19 | 2001-06-13 | 吉林省力源药业股份有限公司 | Chinese medicine for treating hepatitis B and its preparing process |
| CN1141101C (en) * | 2000-12-19 | 2004-03-10 | 吉林省力源药业股份有限公司 | Chinese medicine for treating hepatitis B and its preparing process |
| CN1498892A (en) * | 2002-11-05 | 2004-05-26 | 维京仲华（上海）生物医药科技有限公 | Extract of general glycoside in picrorhiza rhizome as well as preparation method and application |
| CN1488637A (en) * | 2003-09-05 | 2004-04-14 | 北京深文医药科技开发有限公司 | Method for preparing total aglycone extract of radix picrorrhizae |
| CN1590396A (en) * | 2003-09-05 | 2005-03-09 | 天津药物研究院 | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686201A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103381217B (en) | A kind of Liuweibuxue capsule and method of quality control thereof and application | |
| US20110059124A1 (en) | The quality control method and application of a kind of ganoderma lucidum spore oil fat emulsion | |
| CN106937959B (en) | A kind of antitumor extra large Blatta seu periplaneta extract and its preparation technology and detection method and purposes | |
| CN101322748B (en) | Hypericum perforatum total flavones and formulation preparation and quality testing method | |
| CN1325079C (en) | Chinese medicine picrorhiza extract possessing anti hepatitis B virus activity and its preparation method | |
| CN101428090B (en) | Tibet picrorhiza rhizome composition with specific spectrum effect relationship | |
| CN101057890A (en) | Traditional Chinese medicinal composition for treating coronary heart disease and its preparation method, preparations and its application | |
| CN105267274A (en) | Atractylenolide extract having antiparkinsonian effect, preparation method and application thereof | |
| CN100464755C (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN1709417A (en) | Ainsliaea fragrans champ extract and its preparing method | |
| CN1990500A (en) | Liver-fibrosis-resistant asiatic centella triterpenoid saponin and its preparation process | |
| CN103239487A (en) | Bilobalide injection and content determination method | |
| CN103091412B (en) | Method for detecting ginkgolide effective parts | |
| CN102140101A (en) | Method for preparing Herperione, application thereof, capsule thereof, preparation method and application of capsule | |
| CN100584345C (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, extraction method and application | |
| CN103163252B (en) | Determination method for total ginkgolic acid in ginkgolide composition | |
| CN103055191A (en) | Preparation method and quality detection method of traditional Chinese medicine for treating hematuresis caused by nephritis | |
| CN1251700C (en) | Application of flatstem milkvetch seed and its extract in the preparation of anti hepatic fibrosis medicine and anticancer medicine | |
| CN103610798A (en) | Active site of oldenlandia diffusa as well as preparation method and application thereof | |
| CN1923268B (en) | Medicinal composition for treating rhinitis, its preparing method and quality controlling means | |
| CN103239486B (en) | Residue determination method of ginkgo lactone composition for treating cardiovascular and cerebrovascular diseases | |
| CN1660184B (en) | Combination of medicaiton containing extractive of herb of glabrous sarcandra, and preparation method and application | |
| CN104586925B (en) | Redback christmashush root extract and preparation method and preparation treatment hepatitis B medicine application | |
| CN103202839B (en) | Ginkgolide composition for treating cardiovascular and cerebrovascular diseases | |
| CN101584730A (en) | Injection preparation and quality control method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070711 Termination date: 20170328 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |